|Bid||48.610 x 1400|
|Ask||48.630 x 400|
|Day's Range||48.610 - 48.820|
|52 Week Range||36.810 - 50.240|
|PE Ratio (TTM)||11.77|
|Dividend & Yield||1.64 (3.44%)|
|1y Target Est||N/A|
Diabetes and Cardiovascular is one of Sanofi’s (SNY) most important business units, contributing over 20% of its pharmaceutical revenue. The franchise reported 10.7% revenue growth to 1.8 billion euros ...
In 2Q17, Sanofi Genzyme (SNY) reported revenue growth of 13.5% to 1.7 billion euros. Considering a constant structure and constant exchange rates, the growth was 14.4%. Sanofi Genzyme, which includes product ...
At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros. The above chart shows Sanofi’s…